Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dalbavancin - Durata Therapeutics

Drug Profile

Dalbavancin - Durata Therapeutics

Alternative Names: A-A-1; BI-397; Dalbavancin hydrochloride; Dalvance; MDL-63,397; V-Glycopeptide; VER 001; VGE; Xydalba; Zevan; Zeven

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vicuron Pharmaceuticals
  • Developer Cipher Pharmaceuticals; Durata Therapeutics; Pfizer
  • Class Antibacterials; Glycopeptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors; Peptidoglycan inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteomyelitis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Skin and soft tissue infections
  • Phase II Bacterial endocarditis; Osteomyelitis
  • No development reported Bacterial infections; Catheter infections; Diabetic foot ulcer; Gonorrhoea; Pneumonia

Most Recent Events

  • 19 Jan 2022 Launched for Skin and soft tissue infections in Canada (IV)
  • 23 Jul 2021 Launched for Skin and soft tissue infections (In adolescents, In children, In infants, In neonates) in USA (IV)
  • 23 Jul 2021 Preregistration for Skin and soft tissue infections (In adolescents, In children, In infants, In neonates) in USA (IV), prior to July 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top